Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | How our expanding knowledge of pre-malignant conditions may impact clinical decision-making

Rena Buckstein • 10 Dec 2023
ASH 2023
General

Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, comments on whether the expanding knowledge around pre-malignant pathologies, namely clonal hematopoiesis of indeterminate potential (CHIP), may impact treatment approaches and clinical practice in patients with hematological malignancies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Abbvie: Honoraria; Taiho: Honoraria, Research Funding; BMS: Honoraria, Research Funding.

More from Rena Buckstein

2:21
Unmet needs in LR-MDS: RBC transfusion-dependence
Rena Buckstein • 10 Dec 2023
0:47
Screening for CHIP to detect potential TMNs in cancer treatment
Rena Buckstein • 10 Dec 2023
3:24
The impact of CHIP on clinical outcomes in older patients with lymphoma undergoing chemotherapy
Rena Buckstein • 10 Dec 2023
Key highlights from iwMDS 2022
Amer Zeidan et al. • 24 Jun 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals